Sector News

Procter & Gamble is still eyeing Pfizer's consumer health unit

April 5, 2018
Life sciences

Don’t lose all hope for a Pfizer consumer health sale.

Procter & Gamble is still at the negotiating table, CNBC’s David Faber reports, though “it doesn’t appear likely” the two sides will reach an agreement because “they are far apart on price,” he said.

Whereas Pfizer had been hoping to bring in some $20 billion through a sale, P&G is “hovering closer to a $15 or $16 billion number,” Faber said, adding that “the gap there is simply too large to bridge, at least at present.”

A transaction for the Big Pharma, which put its OTC unit on the block back in October, looked all but impossible after Reckitt Benckiser and GlaxoSmithKline dropped out of the running late last month. Reckitt had tried unsuccessfully to snag a piece of Pfizer’s portfolio, while Glaxo opted instead to buy out Novartis’ share of their consumer health joint venture.

Now, though, there could be another JV in the works, Faber said. Pfizer “might pursue a joint venture of some kind, not with Procter & Gamble but the aforementioned two other bidders,” he said, noting that the process was in the early stages.

Of course, Pfizer could decide to keep the unit after all, a scenario some industry watchers have predicted. As a major beneficiary of U.S. tax reform, Pfizer doesn’t need the cash. “[I]f no one is prepared to pay their asking price, then why sell it?” Polar Capital partner Daniel Mahony put it recently to Bloomberg.

Others, though—such as UBS Group’s Michael Leuchten—argue that OTC valuations will only sink as online retailers heap pressure on drugstores.

“The world has changed,” he told the news service. “That means these businesses or assets probably won’t be able to fetch the multiples they have in the past.”

Whatever happens, Pfizer will likely want to wrap things up quickly. “The hope is that in the next few weeks they will reach a conclusion of some kind,” Faber said.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.